Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
iwCAR-T 2023
The 5th International Workshop on CAR-T
14–16 April 2023 | Scottsdale, AZ
Explore presentations by leading experts from iwCAR-T 2023 below. Click here to view roundtable discussions.
Session 1: Current challenges
Suppression mechanisms of CAR‐T cells
Marco Davila Roswell Park, Buffalo, NY, United States
Enforcing memory programs to enhance CAR‐T persistence
Evan Weber Children's Hospital of Philadelphia, Philadelphia, PA, United States
Cladribine & cyclophosphamide lymphodepletion
Filip Ionescu Moffitt Cancer Center, Tampa, FL, United States
Single cell analysis of CAR-T response and toxicity
Michael Green MD Anderson Cancer Center, Houston, TX, United States
Session 2: Toxicity
CRS/ICANS prophylaxis attempts
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Update on management of neuro‐toxicities/CRS in CAR‐T
Bianca Santomasso Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Session 3: CAR‐T in ALL
ZUMA‐3 – brexucabtagene autoleucel for adult ALL
Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
CD19‐targeted CAR T‐cell in R/R B‐cell ALL/Auto
Claire Roddie University College London, London, United Kingdom
Bispecific LV20.19 and trispecific duo CAR20.19.22
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
CAR‐T for T‐ALL
Maksim Mamonkin Baylor College of Medicine, Houston, TX, United States
Session 4: CAR‐T in AML
Single‐cell analysis to develop new CAR therapies
Sebastian Kobold Ludwig Maximilian University, Munich, Germany
Outcomes in early‐phase CAR‐T clinical trials
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
NK cell‐based immunotherapy
Roman Shapiro Dana-Farber Cancer Institute, Boston, MA, United States
Updates on bispecifics
Marion Subklewe LMU Hospital Munich, Munich, Germany
Session 5: CAR‐T in lymphoma
Brexucabtagene autoleucel in R/R MCL
Michael Jain H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
CARs for primary CNS lymphoma
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Alternative targets in lymphoma (CD22, ROR1)
David Miklos Stanford University, Stanford, CA, United States
Liso‐cel for the treatment of B‐cell lymphoma
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
CRISPR‐edited allogeneic anti‐CD19 CAR-T for for R/R B‐cell NHL
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Bispecifics in DLBCL
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Bispecific treatments in FL and MCL
Tycel Phillips City of Hope, CA, United States
Session 6: Improving vein‐to‐vein time
Varnimcabtagene autoleucel for R/R B‐cell malignancies
Valentín Ortiz-Maldonado Hospital Clínic de Barcelona, Barcelona, Spain
Challenges and approaches for rapid manufacturing
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Keynote lecture
Driving CAR T‐cells forward
Renier Bretjens Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Session 7: CAR‐T in multiple myeloma
Updates from the Myeloma CAR‐T Consortium:
Doris Hansen H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
CAR‐T therapy work for high‐risk multiple myeloma patients
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
BCMA and non‐BCMA bispecific antibodies
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Mechanisms of resistance to BCMA‐targeted therapy
Nizar Bahlis Arnie Charbonneau Cancer Institute, Calgary, Canada
AlloCART – will they be the solution to access in myeloma?
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
GPRC5D CAR‐T in myeloma
Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States
Session 8: CAR‐T in CLL
Immune resistance in CLL
Joseph Melenhorst Cleveland Clinic, Cleveland, OH, United States
Update on TRANSCEND – liso‐cel in CLL/SLL
Tanya Siddiqi City of Hope, Duarte, CA, United States
CART‐19 with ibrutinib for the treatment of CLL
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
The continued success of the iwCAR-T meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.
iwCAR-T 2023 was supported by:
